SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Bio NC
Innovative Companies Diving into The Neuro Market Ahead of 2021
With the expected Emergency Use Authorization (EUA) of Pfizer-BioNTech and Moderna’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience?
December 9, 2020
 · 
4 min read
 · 
Heather McKenzie
Drug Development
Biotechs Developing Innovative Ways to Activate the Immune System Against COVID-19
BioSpace spoke with a few companies that have some ingenious ideas at different stages of preclinical and clinical development.
December 8, 2020
 · 
7 min read
 · 
Heather McKenzie
Business
Survey Says There is a Disconnect Between Good Intent and Action in D&I Initiatives
Diversity and Inclusion (D&I) have been at the forefront of the national conversation during this momentous year, so BioSpace felt it imperative to reach out to employees in the life sciences industry on this subject in our wide-ranging Fall 2020 Diversity and Inclusion Survey.
December 7, 2020
 · 
7 min read
 · 
Heather McKenzie
Drug Development
Abionic’s cSOFA Score Could Help Hospitals Anticipate COVID-19 Complications
Swiss medtech company Abionic SA announced that they have developed the first COVID-19 severity test, the cSOFA (Covid Sequential Organ Failure Assessment) score, to help doctors quickly and accurately triage cases that come into emergency rooms.
December 7, 2020
 · 
5 min read
 · 
Heather McKenzie
STRO-002 to spread it's wings soon.
Drug Development
Solid Safety Profile in Hand, Sutro Will Expand Reach of Ovarian Cancer Drug STRO-002
As the dose of Sutro Biopharma’s ovarian cancer drug, STRO-002, increased in an ongoing Phase I dose-escalation trial, survival rates have also increased.
December 4, 2020
 · 
3 min read
 · 
Heather McKenzie
Business
Frontier and AbbVie Team Up Against Elusive Protein Targets
Therapies developed using E3 ligase proteins will get a potent infusion, as AbbVie combines its commercialization expertise with Frontier Medicine’s proprietary chemoproteomics platform to develop potentially efficacious therapies for difficult-to-drug protein targets.
December 3, 2020
 · 
3 min read
 · 
Heather McKenzie
BioCapital
AstraZeneca Most Recent Victim of Hackers Posing as Recruiters
As if attempting to steal hard-won research wasn’t bad enough, hackers are now hitting people where it really hurts – with e-documents containing malicious code embedded in false offers of employment.
December 3, 2020
 · 
4 min read
 · 
Heather McKenzie
Taljat David/Shutterstock
FDA
FDA Approves Roche COVID-19 Test that Aims to Test Vaccines’ Antibody Response
The U.S. Food and Drug Administration has given Emergency Use Authorization (EUA) to a COVID-19 test developed by Roche that measures antibodies within the blood.
December 2, 2020
 · 
2 min read
 · 
Heather McKenzie
Drug Development
Widespread Vaccine Uptake Will Likely Require Full Transparency on Side Effects
Physicians are worried that a lack of transparency about side effects might prevent people from going back for a second dose, or even getting the first one.
November 24, 2020
 · 
3 min read
 · 
Heather McKenzie
uniQure CEO Matt Kapusta, Company Courtesy
Drug Development
One Step Forward for Hemophilia Patients – an Even Bigger Step for Gene Therapy
Positive top-line data from UniQure’s Phase III HOPE-B gene therapy trial of etranacogene dezaparvove, an investigational AAV5-based gene therapy, point to a potentially curative treatment for patients with moderate to moderately severe hemophilia B.
November 19, 2020
 · 
3 min read
 · 
Heather McKenzie
New Understanding of eTreg Cells Signals Hope for Inflammatory Diseases
Scientists at St. Jude Children’s Research Hospital have revealed insight into the metabolic signaling pathways influencing eTreg cells that could lead to new therapies for inflammatory diseases and related disorders.
November 19, 2020
 · 
2 min read
 · 
Heather McKenzie
Business
Lead Pharma Teams with Roche on Oral Small Molecules for Immune-Mediated Diseases
Lead Pharma has entered into a collaboration and license agreement with Roche, hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases.
November 18, 2020
 · 
2 min read
 · 
Heather McKenzie
Dr. Satjit Bhusri
Business
Diabetes: COVID-19 Risk Factor and Potential Side Effect
We have known since early on that diabetes is a complicating risk factor for developing severe illness from the SARS-CoV-2 virus that causes COVID-19. The hypothesis is now being floated by members of the medical community that COVID-19 may cause the disease to return – or potentially a unique version of it.
November 18, 2020
 · 
5 min read
 · 
Heather McKenzie
Deals
Sumitovant to Snap Up Development Partner Urovant Sciences
In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma.
November 16, 2020
 · 
2 min read
 · 
Heather McKenzie
Biotech Investors Rolling the Dice with 250% SPAC Surge
Emerging biotech companies have been finding creative ways to explode onto the stock exchange during the COVID-19 pandemic.
November 13, 2020
 · 
2 min read
 · 
Heather McKenzie
Load More